A director of the Company since September 2010, Dr. Csimma also serves on the Board of Directors for Neuralstem, Inc. (nervous system diseases). She has been engaged in strategic advisory roles with the biopharmaceutical and venture capital industries, as well as government and patient organizations.
Dr. Csimma was The Executive Chair of the Board of Directors of Exonics Therapeutics (rare diseases), a director at Vtesse Inc. (rare diseases, acquired by Sucampo in March 2017), and was a President and the founding Chief Executive Officer of Cydan Development, Inc. (therapeutics for orphan diseases) from November 2012 until April 2014, and a director of Cydan from April 2014 until December 2014. She served as Vice President, Drug Development, of Virdante Pharmaceuticals, Inc., from January 2009 to May 2011, prior to which she was a principal of Clarus Ventures, LLC (life sciences venture capital), from 2006 through 2008.
During her tenure at Wyeth Research (pharmaceuticals), Dr. Csimma was Senior Director/Director, Experimental Medicine and Translational Research from 2001 to 2006, and Director, Clinical Research and Development from 2000 to 2001. Prior to Wyeth, Dr. Csimma held various positions, including Associate Director, Clinical Research, with Genetics Institute from 1988 to 2000, and was a Clinical Pharmacist with Dana-Farber Cancer Institute from 1983 to 1988.
Dr. Csimma holds B.S. and Doctor of Pharmacy degrees from the Massachusetts College of Pharmacy and Allied Health Sciences, and a Master of Health Professions from Northeastern University.